Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated with the ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

A systematic review of randomized controlled trials (RCTs) found that weight-loss interventions were associated with improvements in some polycystic ovary syndrome (PCOS) symptoms, including ...

Here's a deeper look into four promising treatment options. T-DXd proves active against HER2-positive, advanced metastatic ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be ...

In their recent study, Dr. Hurvitz and her research team were interested in determining if T-DXd had improved efficacy for patients with BM compared to other treatments. To approach this, they ...

Studies have called into question whether patients with HER2-low breast cancer are being identified and classified accurately.

MSK developed a cancer drug that’s giving people with stage 4 breast cancer new hope. The drug, T-DXd, was approved in 2022. T-DXd is now being tested on other cancers and is changing the way doctors ...

Trastuzumab is an antibody that blocks the growth signals sent out by HER2. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC). ADCs have powerful chemotherapy drugs attached to ...